C22H28FO8P.2Na
Neat
470.43 2*22.99
G8JMD5H7QP; RRT 0.55 bsp degradant; 1201919-11-0; Sodium ((1R, 3S, 10aS, 10bR, 11S, 12aS)-10b-fluoro-1, 11-dihydroxy-3, 10a, 12a-trimethyl-2, 8-dioxo-3, 4, 4a, 4b, 5, 6, 11, 12-octahydrochrysen-1-yl)methyl phosphate; 2, 8-Chrysenedione, 10b-fluoro-1, 3, 4, 4a, 4b, 5, 6, 10a, 10b, 11, 12, 12a-dodecahydro-1, 11-dihydroxy-3, 10a, 12a-trimethyl-1-((phosphonooxy)methyl)-, sodium salt (1:2), (1R, 3S, 4aS, 4bS, 10aS, 10bR, 11S, 12aS)-; 2, 8-Chrysenedione, 10b-fluoro-1, 3, 4, 4a, 4b, 5, 6, 10a, 10b, 11, 12, 12a-dodecahydro-1, 11-dihydroxy-3, 10a, 12a-trimethyl-1-[(phosphonooxy)methyl]-, sodium salt (1:2), (1R, 3S, 4aS, 4bS, 10aS, 10bR, 11S, 12aS)-; Disodium 10b-fluoro-1, 3, 4, 4a, 4b, 5, 6, 10a, 10b, 11, 12, 12a-dodecahydro-1, 11-dihydroxy-3, 10a, 12a-trimethyl-1-((phosphonooxy)methyl)-2, 8-chrysenedione, (1R, 3S, 4aS, 4bS, 10aS, 10bR, 11S, 12aS)-; Disodium 10b-fluoro-1, 3, 4, 4a, 4b, 5, 6, 10a, 10b, 11, 12, 12a-dodecahydro-1, 11-dihydroxy-3, 10a, 12a-trimethyl-1-[(phosphonooxy)methyl]-2, 8-Chrysenedione, (1R, 3S, 4aS, 4bS, 10aS, 10bR, 11S and 12aS)-; UNII-G8JMD5H7QP; Betamethasone impurity 70
disodium;[(1R, 3S, 4aS, 4bS, 10aS, 10bR, 11S, 12aS)-10b-fluoro-1, 11-dihydroxy-3, 10a, 12a-trimethyl-2, 8-dioxo-3, 4, 4a, 4b, 5, 6, 11 and 12-octahydrochrysen-1-yl]methyl phosphate
InChI=1S/C22H30FO8P.2Na/c1-12-8-16-15-5-4-13-9-14(24)6-7-19(13,2)22(15,23)17(25)10-20(16,3)21(27,18(12)26)11-31-32(28,29)30;;/h6-7,9,12,15-17,25,27H,4-5,8,10-11H2,1-3H3,(H2,28,29,30);;/q;2*+1/p-2/t12-,15-,16-,17-,19-,20-,21+,22-;;/m0../s1